Natixis’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$20.9K Hold
1,157
﹤0.01% 1008
2025
Q4
$25.2K Buy
1,157
+437
+61% +$12.5K ﹤0.01% 1028
2025
Q3
$23.5K Hold
720
﹤0.01% 960
2025
Q2
$25.6K Sell
720
-65
-8% -$2.11K ﹤0.01% 918
2025
Q1
$26K Sell
785
-64
-8% -$2.29K ﹤0.01% 859
2024
Q4
$27.6K Sell
849
-162
-16% -$6.71K ﹤0.01% 919
2024
Q3
$49.3K Sell
1,011
-54
-5% -$2.88K ﹤0.01% 787
2024
Q2
$47.2K Sell
1,065
-339
-24% -$15.6K ﹤0.01% 788
2024
Q1
$78.8K Sell
1,404
-618
-31% -$37.3K ﹤0.01% 795
2023
Q4
$122K Sell
2,022
-106
-5% -$6.72K ﹤0.01% 762
2023
Q3
$143K Sell
2,128
-993
-32% -$69K ﹤0.01% 749
2023
Q2
$215K Sell
3,121
-702
-18% -$45.9K ﹤0.01% 733
2023
Q1
$184K Sell
3,823
-237
-6% -$11.6K ﹤0.01% 751
2022
Q4
$203K Buy
+4,060
New +$197K ﹤0.01% 821
2022
Q2
Sell
-7,974
Closed -$290K 1271
2022
Q1
$290K Sell
7,974
-108
-1% -$4.27K ﹤0.01% 1070
2021
Q4
$377K Buy
8,082
+686
+9% +$34.8K ﹤0.01% 1086
2021
Q3
$372K Buy
+7,396
New +$308K ﹤0.01% 1060

Other funds holding LEGN

Natixis's LEGN Position: Q1 2026 in Review

Natixis held its Legend Biotech (LEGN) position steady in Q1 2026 at 1,157 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

Natixis first reported a position in LEGN in Q3 2021 and has held it in 17 quarters since. The position peaked at $377K in Q4 2021. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Natixis held 1,157 shares of Legend Biotech worth $20.9K as of Q1 2026.
  • Natixis left its Legend Biotech share count unchanged in Q1 2026.
  • Legend Biotech made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1008 holding.
  • Natixis first reported a position in Legend Biotech in Q3 2021 and has held it in 17 quarters since.
  • Natixis's Legend Biotech position peaked at $377K in Q4 2021.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.